Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation.
10.3904/kjim.2013.28.6.639
- Author:
Hal E BROXMEYER
1
Author Information
1. Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA. hbroxmey@iupui.edu
- Publication Type:Research Support, N.I.H., Extramural ; Review
- Keywords:
Dipeptidyl peptidase 4;
Hematopoietic stem cell transplantation;
Cytokines;
Tissue therapy;
Regenerative medicine
- MeSH:
Animals;
*Cord Blood Stem Cell Transplantation;
Dipeptidyl Peptidase 4/*metabolism;
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use;
Hematopoiesis/*drug effects;
Hematopoietic Stem Cells/*drug effects/enzymology;
Humans;
Regenerative Medicine/*methods;
Signal Transduction/drug effects
- From:The Korean Journal of Internal Medicine
2013;28(6):639-645
- CountryRepublic of Korea
- Language:English
-
Abstract:
Dipeptidylpeptidase (DPP) 4, also known as CD26, is an enzyme present on the surface of a number of different cell types. It is also found within cells and as a soluble protein in body fluids. It can specifically truncate proteins at the penultimate N-terminus residue for some amino acids, such as alanine, proline, serine, and perhaps others. DPP4 has been implicated in regulating the in vitro and in vivo functional activities of a number of hematopoietically active molecules, and this information, along with that on inhibition of DPP4, has been studied in efforts to enhance hematopoietic cell transplantation (HCT), hematopoiesis after stress in mouse models, and in the clinical setting of single-unit cord blood (CB) HCT. This article reviews the current status of this compound's effects on regulatory proteins, the field of CB HCT, a potential role for modulating DPP4 activity in enhancing single-unit CB HCT in adults, and future aspects in context of other cellular therapies and the area of regenerative medicine.
